MedTrace Logo

CEI Van Outreach Screening Study

NCT01510392 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2018-04-12

No results posted yet for this study

Summary

The primary goal of the trial is to show that optical coherence tomography (OCT) technology can be used to effectively screen for diseases of the eye including glaucoma, macular diseases and keratoconus. Glaucoma is a disease that causes permanent vision loss and is usually accompanied by increased eye pressure. Macular diseases affect sharp, central vision. Keratoconus is a disease that affects the cornea (clear surface covering the colored part of the eye).

Conditions

Interventions

DEVICE

OCT imaging, the FDA Cleared iVue

The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Michael Chiang, MD · Oregon Health and Science University

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-02-02
Completion
2017-02-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01510392 on ClinicalTrials.gov